Redeye revisits LIDDS following a change of analyst, a change of company CEO, and the outcome of a newly conducted rights issue.
Redeye comments on LIDDS’ announcement of the proposed decision on a rights issue to strengthen the company’s financial position.
Redeye comments on LIDDS Q3’22 report. Anders Månsson, who succeeded Nina Herne as CEO of LIDDS in September 2022 provided a glimpse of LIDD...
Redeye comments on LIDDS Q2’22 report. The company advances its projects, in particular with regard to nanodotax and nanoimod.
Redeye maintains its positive view of LIDDS after the Q1 report.
LIDDS' CEO Nina Herne presents at the company's Capital Market Day.
Redeye maintains its positive view and valuation of LIDDS after the report today.
Redeye views the secured financing as a positive step but sees risks with the convertibles agreement putting downward pressure on the share ...
Redeye sees increased pipeline value in a prospective validation of the efficacy of LIDDS' drug candidate with docetaxel.
Redeye maintains a positive view on LIDDS after today's Q2 report.
